Skip to main content

Table 3 Target Volume delineations and radiotherapy planning of GBM and AA

From: Carbon ion radiotherapy boost in the treatment of glioblastoma: a randomized phase I/III clinical trial

Radiotherapy

Target volume

Delineation

Dose/fractionation

Minimal dose coverage

CIRT boost

GTV

MET/FET PET or MRS abnormality, contrast enhancement, FLAIR abnormality representing residual tumor

3.00-6.00 GyE × 3 Fx

95%

PRT

GTV

MET/FET PET or MRS abnormality, contrast enhancement, FLAIR abnormality representing residual tumor

N/A*

N/A*

CTV60

GTV + 0.5 cm margin

2.00 GyE × 30 Fx

95%

CTV50

GTV + 1.5 cm margin

1.67 GyE × 30 Fx

95%

  1. GBM: glioblastoma, AA anaplastic astrocytoma, CIRT carbon ion radiotherapy, GTV gross tumor volume, MET/FET PET C-methionine/18F-fluoro-ethyl-tyrosine positron emission tomography, MRS magnetic resonance spectroscopy, FLAIR fluid-attenuated inversion recovery, N/A not applied, GyE gray-equivalents, Fx fraction, PRT proton radiotherapy, CTV60/50 clinical target volume receiving 60/50 GyE irradiation
  2. * N/A: Since the GTV of PRT is not a target volume to give prescription dose, so “N/A” is marked in these cells
Back to article page

Cancer Communications

ISSN: 2523-3548

Contact us